Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

MK-2206 advances to phase II testing in breast cancer

April 6, 2011

Morphotek acquires tumor-targeting peptide platform from TransMolecular

April 5, 2011

Pan-Akt inhibitor GDC-0068 demonstrates in vivo antitumor effects

April 5, 2011

New inhibitors of cyclin-dependent kinase 9 patented by Novartis

April 5, 2011

Novel microtubule-disrupting agents claimed

April 5, 2011

Glenmark Pharma begins IND-enabling studies for GBR-401

April 5, 2011

Algeta and Genzyme to collaborate on new approach to cancer treatment

April 4, 2011

IPI-926 reduces tumor growth in vivo and advances through clinical development

April 4, 2011

Eisai and PRISM collaborate on inhibitors of complex between CREB-binding protein and catenin beta-1

April 4, 2011

Polaris Pharma begins pivotal studies of ADI-PEG 20

April 4, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 5, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...